This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Analysing almost eight thousand tumours across 33 different cancers, researchers say this marks the first time that a framework was created to understand the role of internal factors in driving such genomic alterations. Genomic research have greatly expanded our understanding of disease pathophysiology over the years.
Congenica, a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale, has announced a two-year extension to its contract for the Hong Kong GenomeProject (HKGP), the first large-scale genome sequencing initiative in Hong Kong.
The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1. According to the press release, the MHRA will be the first drug safety regulator in the world to pilot such a biobank. Genomics England will assist the MHRA with sequencing and genetic material storage.
Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.
The following year, the regulator also approved Rituximab, a monoclonal antibody targeting CD-20 positive B-cells, as a companion treatment of chemotherapy in older diffuse large B-cell lymphoma patients. 2012 – The 100,000 GenomicsProject begins. 2002 – Emergence of CAR-T therapy.
The Human GenomeProject could not have succeeded without the use of bioinformatics. Since the conclusion of the project in 2003, bioinformatics tools have been used to identify genes and elucidate their function with the aim of developing gene-based strategies for disease prevention, diagnosis and treatment.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content